A Two-Part, Single-Dose Study of the Pharmacokinetics of MK-8931 in Subjects With Renal Insufficiency (MK-8931-009 [P08535])
NCT01537757
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
12
Enrollment
INDUSTRY
Sponsor class
Conditions
Alzheimer's Disease
Interventions
DRUG:
MK-8931
Sponsor
Merck Sharp & Dohme LLC